We apologize for a recent technical issue with our email system, which temporarily affected account activations. Accounts have now been activated. Authors may proceed with paper submissions. PhDFocusTM
CFP last date
20 December 2024
Call for Paper
January Edition
IJCA solicits high quality original research papers for the upcoming January edition of the journal. The last date of research paper submission is 20 December 2024

Submit your paper
Know more
The week's pick
Responsive image
Improved Shuffled Frog Leaping Algorithm with Self-Adaptive Shuffling for Fuzzy Logic PD+G Controller Optimization in Robotic Manipulators

Duc Hoang Nguyen
Random Articles
Reseach Article

Application of Monte Carlo Algorithm to Explore Simplified Molecular-Input Line-Entry System based Molecular Descriptors of BACE1 inhibitors for Therapeutic Application in Alzheimer’s Disease

by Md Lutful Islam, Gulabchand K. Gupta
journal cover thumbnail

International Journal of Computer Applications
Foundation of Computer Science (FCS), NY, USA
Volume 182 - Number 11
Year of Publication: 2018
Authors: Md Lutful Islam, Gulabchand K. Gupta
10.5120/ijca2018917745

Md Lutful Islam, Gulabchand K. Gupta . Application of Monte Carlo Algorithm to Explore Simplified Molecular-Input Line-Entry System based Molecular Descriptors of BACE1 inhibitors for Therapeutic Application in Alzheimer’s Disease. International Journal of Computer Applications. 182, 11 ( Aug 2018), 40-47. DOI=10.5120/ijca2018917745

@article{ 10.5120/ijca2018917745,
author = { Md Lutful Islam, Gulabchand K. Gupta },
title = { Application of Monte Carlo Algorithm to Explore Simplified Molecular-Input Line-Entry System based Molecular Descriptors of BACE1 inhibitors for Therapeutic Application in Alzheimer’s Disease },
journal = { International Journal of Computer Applications },
issue_date = { Aug 2018 },
volume = { 182 },
number = { 11 },
month = { Aug },
year = { 2018 },
issn = { 0975-8887 },
pages = { 40-47 },
numpages = {9},
url = { https://ijcaonline.org/archives/volume182/number11/29868-2018917745/ },
doi = { 10.5120/ijca2018917745 },
publisher = {Foundation of Computer Science (FCS), NY, USA},
address = {New York, USA}
}
%0 Journal Article
%1 2024-02-07T01:11:11.242503+05:30
%A Md Lutful Islam
%A Gulabchand K. Gupta
%T Application of Monte Carlo Algorithm to Explore Simplified Molecular-Input Line-Entry System based Molecular Descriptors of BACE1 inhibitors for Therapeutic Application in Alzheimer’s Disease
%J International Journal of Computer Applications
%@ 0975-8887
%V 182
%N 11
%P 40-47
%D 2018
%I Foundation of Computer Science (FCS), NY, USA
Abstract

Application of computer science and algorithms are now become an integral part of the drug discovery research. In the current work, well known Monte Carlo (MC) algorithm was used to develop quantitative structure-activity relationship (QSAR) models with molecular descriptors derived from simplified molecular-input line-entry system (SMILES) representation of beta-site APP cleaving enzyme1 (BACE1) inhibitors. A set of BACE1 inhibitors was obtained from the binding database and subsequently divided into training, test, calibration and external sets. The QSAR models were developed from the training set compounds while other sets used to assess the quality of developed models. With- and without-influence of cyclic rings on inhibitory activity were considered to develop the QSAR models. Best QSAR models were selected based on statistical parameters of final models. High correlation and low standard error values of training, test, calibration and external sets undoubtedly suggested that the selected models were robust and efficient enough to predict the inhibitory activity of the molecules. On evaluation of statistical parameters it was revealed that cyclic rings of molecular scaffold significantly contributed to the inhibition of BACE1. The molecular fragments were found to be crucial to increase or decrease the inhibitory activity of the molecules which indicated that models have mechanistic interpretation. Therefore, important molecular fragments explained by the QSAR models can be used to design new and novel BACE1 inhibitors for therapeutic application in Alzheimer’s disease.

References
  1. Santana, I., Farinha, F., Freitas, S., Rodrigues, V., Carvalho, A. [The Epidemiology of Dementia and Alzheimer Disease in Portugal: Estimations of Prevalence and Treatment-Costs]. Acta Med Port. 2015, 28, 182-8.
  2. Alzheimer's, A. 2015 Alzheimer's disease facts and figures. Alzheimers Dement. 2015, 11, 332-84.
  3. Chiang, K., Koo, E.H. Emerging therapeutics for Alzheimer's disease. Annu Rev Pharmacol Toxicol. 2014, 54, 381-405.
  4. Masters, C.L., Bateman, R., Blennow, K., Rowe, C.C., Sperling, R.A., Cummings, J.L. Alzheimer's disease. Nat Rev Dis Primers. 2015, 1, 15056.
  5. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001, 81, 741-66.
  6. Ghosh, A.K., Osswald, H.L. BACE1 (beta-secretase) inhibitors for the treatment of Alzheimer's disease. Chem Soc Rev. 2014, 43, 6765-813.
  7. Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999, 286, 735-41.
  8. Cui, H., Hung, A.C., Klaver, D.W., Suzuki, T., Freeman, C., Narkowicz, C., et al. Effects of heparin and enoxaparin on APP processing and Abeta production in primary cortical neurons from Tg2576 mice. PLoS One. 2011, 6, e23007.
  9. Citron, M. Beta-secretase as a target for the treatment of Alzheimer's disease. J Neurosci Res. 2002, 70, 373-9.
  10. De Strooper, B., Vassar, R., Golde, T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010, 6, 99-107.
  11. Luo, Y., Bolon, B., Kahn, S., Bennett, B.D., Babu-Khan, S., Denis, P., et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci. 2001, 4, 231-2.
  12. Christensen, M.A., Zhou, W., Qing, H., Lehman, A., Philipsen, S., Song, W. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol. 2004, 24, 865-74.
  13. Nishitomi, K., Sakaguchi, G., Horikoshi, Y., Gray, A.J., Maeda, M., Hirata-Fukae, C., et al. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J Neurochem. 2006, 99, 1555-63.
  14. Zivkovic, J.V., Trutic, N.V., Veselinovic, J.B., Nikolic, G.M., Veselinovic, A.M. Monte Carlo method based QSAR modeling of maleimide derivatives as glycogen synthase kinase-3beta inhibitors. Comp Biol Med. 2015, 64, 276-82.
  15. Roy, K., Kar, S., Das, R.N. A Primer on QSAR/QSPR Modeling Fundamental Concepts, Springer International Publishing, 2015.
  16. Duchowicz, P.R., Comelli, N.C., Ortiz, E.V., Castro, E.A. QSAR study for carcinogenicity in a large set of organic compounds. Current Drug Safety. 2012, 7, 282-8.
  17. Talevi, A., Bellera, C.L., Di Ianni, M., Duchowicz, P.R., Bruno-Blanch, L.E., Castro, E.A. An integrated drug development approach applying topological descriptors. Current Comp-Aided Drug Design. 2012, 8, 172-81.
  18. Randic, M., Basak, S.C. A new descriptor for structure-property and structure-activity correlations. J Chem Inf Comp Sci. 2001, 41, 650-6.
  19. Junkes Bda, S., Arruda, A.C., Yunes, R.A., Porto, L.C., Heinzen, V.E. Semi-empirical topological index: a tool for QSPR/QSAR studies. J Mol Model. 2005, 11, 128-34.
  20. Ivanciuc, O. Chemical graphs, molecular matrices and topological indices in chemoinformatics and quantitative structure-activity relationships. Current Comp-Aided Drug Design. 2013, 9, 153-63.
  21. Weininger, D. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. J Chem Inf Comp Sci. 1988, 28, 31-6.
  22. Weininger, D., Weininger, A., Weininger, J.L. SMILES. 2. Algorithm for generation of unique SMILES notation J Chem Inf Comp Sci. 1989, 29, 97-101.
  23. Weininger, D. SMILES. 3. Depict. Graphical depiction of chemical structures. J Chem Inf Comp Sci. 1990, 30, 237-43.
  24. Toropov, A.A., Benfenati, E. SMILES in QSPR/QSAR Modeling: results and perspectives. Curr Drug Discov Technol. 2007, 4, 77-116.
  25. Toropov, A.A., Benfenati, E. SMILES as an alternative to the graph in QSAR modelling of bee toxicity. Comput Biol Chem. 2007, 31, 57-60.
  26. Veselinovic, A.M., Veselinovic, J.B., Zivkovic, J.V., Nikolic, G.M. Application of SMILES Notation Based Optimal Descriptors in Drug Discovery and Design. Curr Topics Med Chem. 2015, 15, 1768-79.
  27. Toropov, A.A., Toropova, A.P., Diaza, R.G., Benfenati, E., Gini, G. SMILES-based optimal descriptors: QSAR modeling of estrogen receptor binding affinity by correlation balance. Struct Chem. 2012, 23, 529–44.
  28. Veselinovic, A.M., Milosavljevic, J.B., Toropov, A.A., Nikolic, G.M. SMILES-based QSAR models for the calcium channel-antagonistic effect of 1,4-dihydropyridines. Archiv der Pharmazie. 2013, 346, 134-9.
  29. Veselinovic, A.M., Milosavljevic, J.B., Toropov, A.A., Nikolic, G.M. SMILES-based QSAR model for arylpiperazines as high-affinity 5-HT(1A) receptor ligands using CORAL. European journal of pharmaceutical sciences : official journal of the Euro Fed Pharm Sci. 2013, 48, 532-41.
  30. Veselinovic, J.B., Toropov, A.A., Toropova, A.P., Nikolic, G.M., Veselinovic, A.M. Monte carlo method-based QSAR modeling of penicillins binding to human serum proteins. Arch Pharm (Weinheim). 2015, 348, 62-7.
  31. Worachartcheewan, A., Mandi, P., Prachayasittikul, V., Toropova, A.P., Toropov, A.A., Nantasenamat, C. Large-scale QSAR study of aromatase inhibitors using SMILES-based descriptors. Chemo Intell Lab Syst. 2014, 138, 120-6.
  32. Li, Q., Ding, X., Si, H., Gao, H. QSAR model based on SMILES of inhibitory rate of 2, 3-diarylpropenoic acids on AKR1C3. Chemo Intell Lab Syst. 2014, 139, 120-6.
  33. Toropova, A.P., Toropov, A.A., Veselinovic, J.B., Miljkovic, F.N., Veselinovic, A.M. QSAR models for HEPT derivates as NNRTI inhibitors based on Monte Carlo method. Europ J Med Chem. 2014, 77, 298-305.
  34. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001, 46, 3-26.
  35. Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W., Kopple, K.D. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002, 45, 2615-23.
  36. Toropova, M.A., Toropov, A.A., Raska, I., Jr., Raskova, M. Searching therapeutic agents for treatment of Alzheimer disease using the Monte Carlo method. Comput Biol Med. 2015, 64, 148-54.
  37. Kubinyi, H., Hamprecht, F.A., Mietzner, T. Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices. J Med Chem. 1998, 41, 2553-64.
  38. Roy, K., Mitra, I., Kar, S., Ojha, P.K., Das, R.N., Kabir, H. Comparative studies on some metrics for external validation of QSPR models. J Chem Inf Model. 2012, 52, 396-408.
  39. Ojha, P.K., Mitra, I., Das, R.N., Roy, K. Further exploring rm2 metrics for validation of QSPR models. Chemo Intell Lab Syst. 2011, 107, 194-205.
  40. Ojha, P.K., Roy, R. Comparative QSARs for antimalarial endochins: importance of descriptor-thinning and noise reduction prior to feature selection. Chemo Intell Lab Syst. 2011, 109, 146-61.
Index Terms

Computer Science
Information Sciences

Keywords

Alzheimer’s disease BACE1 inhibitors QSAR Monte Carlo algorithm SMILES

Powered by PhDFocusTM